Fred R. Hirsch

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

2.8Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973

Top 11%

1.9DataRank

Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Papers

Driven by 30 papers — median percentile 50. Top paper: “An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis”.

An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis

Nature(2023)10.1038/s41586-023-06797-9

N/A

3.9DataRank · unranked

186 citations

Samarth Hegde, Matthew D. Park, Barbara B. Maier, Leanna Troncoso, Jessica Le Bérichel +33 more

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology(2021)10.1001/jamaoncol.2021.2209

N/A

3.1DataRank · unranked

105 citations

Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.09.013

N/A

2.3DataRank · unranked

79 citations

Mary W. Redman, Susanne M. Arnold, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973

Top 11%

1.9DataRank

Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance)

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.07.005

N/A

1.5DataRank · unranked

41 citations

William G. Richards, David H. Harpole, Karla V. Ballman, Ming-Sound Tsao, Zhengming Chen +18 more

The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.03.003

Top 28%

0.718DataRank

Top 28%16 citations

Ramón Rami–Porta, Ming-Sound Tsao, Luis M. Montuenga, Katherine K. Nishimura, Dorothy J. Giroux +6 more

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.10.002

N/A

0.659DataRank · unranked

13 citations

Mary W. Redman, James Moon, Francesco Agustoni, Roy S. Herbst, Thomas J. Semrad +6 more

Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9532

N/A

0.552DataRank · unranked

9 citations

Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick +6 more

Extracellular vesicles containing SARS‐CoV‐2 proteins are associated with multi‐organ dysfunction and worse outcomes in patients with severe COVID‐19

Journal of Extracellular Vesicles(2024)10.1002/jev2.70001

N/A

0.373DataRank · unranked

11 citations

Marisol Arroyo‐Hernández, Sabrina La Salvia, Muthukumar Gunasekaran, Edward M. Pickering, Stephanie V. Avila +18 more

Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

Lung Cancer(2023)10.1016/j.lungcan.2023.107423

Top 72%

0.109DataRank

Top 72%1 citations

Chih–Yuan Hsu, Jennifer G. Whisenant, Melina E. Marmarelis, Carolyn J. Presley, Karen L. Reckamp +24 more

Contrasting interferon-mediated antiviral responses in human lung adenocarcinoma cells

Journal of Virology(2025)10.1128/jvi.00469-25

N/A

0.104DataRank · unranked

1 citations

Sara S. El Zahed, Umut Karakus, Hanspeter Niederstrasser, Boning Gao, Kimberly Batten +9 more

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.11.001

N/A

0DataRank · unranked

54 citations

Noy Meshulami, Alessandro Russo, Florian Krammer, Adolfo Garcı́a-Sastre, Philip C. Mack +14 more

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.001

N/A

0DataRank · unranked

32 citations

Mary W. Redman, Lauren A. Byers, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Assessing the association of diabetes with lung cancer risk

Translational Lung Cancer Research(2021)10.21037/tlcr-21-601

N/A

0DataRank · unranked

31 citations

Antonios Charokopos, Stacyann Bailey, Emily J. Gallagher, Fred R. Hirsch, Derek LeRoith +2 more

Functional

UNC Libraries(2020)10.17615/w0zc-fn45

N/A

0DataRank · unranked

0 citations

Witold Rzyman, Todd Auman, Amy S. Etheridge, Osman Mirza, Jacek Jassem +12 more

SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9623

Top 100%

0DataRank

Top 100%0 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Journal of Experimental & Clinical Cancer Research(2022)10.1186/s13046-022-02379-1

N/A

0DataRank · unranked

109 citations

Alessandro Russo, Óscar Arrieta, Murat Ak, Feliciano Barrón, Muthukumar Gunasekaran +20 more

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0741

N/A

0DataRank · unranked

55 citations

Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst +7 more

Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Open Forum Infectious Diseases(2022)10.1093/ofid/ofac171

N/A

0DataRank · unranked

15 citations

Fred R. Hirsch, Lawrence H. Kushi, Wendy N. Nembhard, James M. Crawford, Nicholas J. Mantis +92 more

29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC)

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0029

N/A

0DataRank · unranked

1 citations

Xing Hua, Khaled Tolba, David Fabrizio, Lee A. Albacker, Ryan Brennick +11 more

Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9576

N/A

0DataRank · unranked

2 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, David R. Gandara, Fred R. Hirsch, Philip C. Mack +14 more

Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies

Cancer Cell(2023)10.1016/j.ccell.2023.08.007

N/A

0DataRank · unranked

8 citations

Simon Heeke, Benjamin J. Drapkin, Anna Solta, Ildikó Kovács, Kristiina Boettiger +16 more

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

The Lancet Oncology(2020)10.1016/s1470-2045(20)30475-7

N/A

0DataRank · unranked

125 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +21 more

Role of Lactate in the Regulation of Transcriptional Activity of Breast Cancer-Related Genes and Epithelial-to-Mesenchymal Transition Proteins: A Compassion of MCF7 and MDA-MB-231 Cancer Cell Lines

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.23.533060

N/A

0DataRank · unranked

13 citations

Janel L. Martinez, Shivaun Lueke Pickard, Hui Yu, Fred R. Hirsch, Christopher J. Rivard +2 more

The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9035

N/A

0DataRank · unranked

0 citations

Mary W. Redman, David Kozono, Sam Callis, Hanna Tukachinsky, Khaled Tolba +14 more

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.01.005

N/A

0DataRank · unranked

460 citations

Sanja Đačić, Ignacio I. Wistuba, Lynette M. Sholl, Prasad S. Adusumilli, Lukas Bubendorf +38 more

Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

Vaccines(2024)10.3390/vaccines12070713

N/A

0DataRank · unranked

1 citations

Chih–Yuan Hsu, Ananda M. Rodilla, Jorge Gómez, Jazz Cagan, Yuanhui Huang +19 more

Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection

Nature Medicine(2025)10.1038/s41591-025-03780-x

N/A

0DataRank · unranked

45 citations

Neeraj Kumar, Swaraj Nanda, Siddharth Singi, Eugene Fluder, Ricky Kwan +21 more

Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.06.012

N/A

0DataRank · unranked

17 citations

Ioannis Vathiotis, Debdatta Halder, Utsav Sen, Xuejun Wang, Misty Dawn Shields +5 more

A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.06.001

N/A

0DataRank · unranked

547 citations

Paolo Ocampo, Yuhe Xia, Judy Zhong, Prudence A. Russell, Yuko Minami +39 more

Fred R. Hirsch

Indexed papers

Top data-sharing exemplar

Papers